


The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

ADAM J. FEIN, PHD

OCTOBER 2025



DRUG CHANNELS INSTITUTE
An HMP Global Company

COPYRIGHT

© 2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by HMP Omnimedia, LLC, Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and HMP Omnimedia, LLC, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. HMP Omnimedia, LLC, and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing in this report should be interpreted as an opinion by HMP Omnimedia, LLC, Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of HMP Global.

LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. **This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.**

If you would like to quote from or otherwise cite the report, here is a suggested citation:

The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors,
Drug Channels Institute, 2025.

The complete End User License Agreement is available at <https://drugch.nl/2025-26EULA> .

Please contact us at dcisupport@hmpglobal.com if you would like to upgrade the license at any time after purchase. You will pay only the difference in license fee.

ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the President of Drug Channels Institute (DCI), an HMP Global company. DCI helps its customers make sense of pharmaceutical economics and the increasingly complex pharmacy distribution and reimbursement system.

Dr. Fein is one of the country's foremost experts on the pharmaceutical industry. He has published hundreds of academic and industry articles. Dr. Fein has contributed to and is regularly quoted in such national publications as *The Wall Street Journal*, *The New York Times*, and many others.



His popular and influential [Drug Channels](https://www.drugchannels.net) website is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. *Drug Channels* is the only place where you'll find a serious discussion of PBMs, drug pricing, and pharmacy economics, all explained with humor and a healthy dose of pop culture.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and his undergraduate degree from Brandeis University. He lives in Philadelphia with his wife and business partner, Paula.

Contact information:

Adam J. Fein, Ph.D.
Drug Channels Institute
1515 Market Street, Suite 1660
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: afein@drugchannels.net
LinkedIn: <https://www.linkedin.com/in/adamjfein/>

Visit Dr. Fein's Drug Channels blog for the latest industry updates.



DRUG CHANNELS

Expert Insights on Pharmaceutical Economics
and the Drug Distribution System

www.DrugChannels.net



ABOUT DRUG CHANNELS INSTITUTE

[Drug Channels Institute \(DCI\)](#) is a leading source of industry research about pharmaceutical economics and the drug distribution system.



DCI hosts live video webinars during which Dr. Fein discusses trends and policies that affect the pharmaceutical industry and its channels. [Click here to view our current and previous video webinars.](#)

DCI also combines Dr. Fein’s expertise and innovative analysis—such as this *2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors*—into interactive e-learning modules that offer your team a thorough grounding in crucial industry topics. [Click here to view a list of our e-learning modules.](#) These online learning tools explain highly complex economic and business data and concepts so you can:

- Make better decisions to achieve your business goals
- Improve relationships with key accounts
- Understand your customers, channels, and the economics of the U.S. pharmaceutical industry

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 1660
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.DrugChannelsInstitute.com
Email: paula@drugchannels.net
LinkedIn: <https://www.linkedin.com/in/paulafein/>



INTRODUCTION AND GUIDE TO THE 2025-26 REPORT

Since the previous edition of this report, pharmacy and healthcare provider markets have continued to post robust revenue growth despite a turbulent business and political environment. During this period of volatility, the largest pharmaceutical wholesalers are accelerating their vertical integration efforts while strengthening their economic fundamentals.

This 2025-26 edition of our *Economic Report on Pharmaceutical Wholesalers and Specialty Distributors* examines the most crucial commercial, political, financial, and legal forces driving industry change:

- Wholesalers' U.S. drug distribution revenues continued to expand. We project that drug distribution revenues for the Big Three public companies—Cencora, Cardinal Health, and McKesson—will reach \$871 billion in 2025. For each of the past four years, these companies have experienced double-digit revenue growth despite downward pressure from reductions in the list prices of select brand-name medications and the increasing substitution of lower-priced biosimilars for higher-priced reference products.
- Anti-obesity GLP-1 agonist drugs remained the most significant driver of wholesalers' revenue. Over the past five years, increases in revenue from the distribution of GLP-1 products have accounted for nearly 30% of wholesalers' total distribution revenue growth.
- Over the past three years, the Big Three companies have spent more than \$16 billion to acquire management service organizations (MSOs) that oversee physician practices in such specialties as gastroenterology, oncology, ophthalmology, and urology. These transactions enable wholesalers to participate directly in the ownership of their downstream physician practice customers. Ownership of MSOs has the potential to protect the companies' channel roles, enable market share expansion, and contribute new sources of revenue and profit. The ultimate strategic benefits of these transactions remain uncertain.
- Biosimilars of provider-administered specialty drugs have emerged as an important source of profits for wholesalers and specialty distributors. Adoption of these products continues to grow as prices fall and payers relax formulary restrictions.
- The retail pharmacy shakeout continued, leading wholesalers to invest in stabilizing the businesses of their smaller, more profitable pharmacy and provider customers. Rite Aid, which had been a significant customer of McKesson, filed for bankruptcy a second time, has closed all of its stores and is liquidating its business and selling off its remaining assets. Walgreens Boots Alliance, Cencora's largest customer, was acquired by a private equity firm and is being restructured into multiple privately held operating companies. Competitive pressures have also led many regional chains to exit the industry.

Meanwhile, the number of independent pharmacies has been surprisingly stable, as store openings offset closures.

- Patient-administered specialty drugs' share of dispensing revenues and payer costs has shrunk for the second consecutive year. The relative growth rates of non-specialty obesity drugs, the introduction of low-priced biosimilars, and the entry of generic specialty drugs drive this trend. Biosimilars of patient-administered biologics do not benefit wholesalers in the same way as provider-administered biosimilars, although these products affect wholesalers' revenues and alter business economics.
- The 340B Drug Pricing Program and the role of 340B contract pharmacies remain highly controversial. Net drug sales under the 340B program now exceed net drug sales under the Medicaid outpatient drug program, while more than 40 manufacturers have altered their policies regarding 340B discounts for external pharmacies. These developments have the potential to compromise wholesalers' cash flow benefits from the program.
- Implementation of the Inflation Reduction Act of 2022 (IRA) has altered the Medicare Part D program and triggered changes in beneficiary out-of-pocket spending, drug prices, and market access strategies. Industry participants have struggled to understand and manage the IRA's intended and unintended consequences. In the short term, wholesalers are benefiting from growing demand for specialty drugs. However, the implementation of maximum fair prices (MFP) has the potential to negatively impact pharmaceutical wholesalers' retail pharmacy and provider customers.
- Wholesalers continue to face uncertain risks due to various federal drug pricing policies. Federal and state governments continued to pursue policies to import drugs originally intended for the Canadian market. However, importation activity remains stalled, and no major wholesaler is participating in these efforts. The prospect of most favored nation (MFN) pricing and tariffs on imported pharmaceutical products could further alter wholesalers' business economics.
- The growth of cash-pay prescriptions and manufacturers' direct-to-patient channels are transforming multiple aspects of the drug channel. While these programs can reshape prescription payment flows, wholesalers have felt limited impact—and in some cases are benefiting—from these developments.
- Over the past year, the stock prices of the publicly traded wholesalers have outperformed broader market indices. The public companies' valuations remain at a small discount to the market.
- The U.S. distribution system is nearing the final implementation of the Drug Supply Chain Security Act (DSCSA), although the U.S. Food and Drug Administration (FDA) has exempted certain DSCSA requirements until as late as November 2026.

- Adoption of cell and gene therapies is growing more slowly than initial projections. Compared with other pharmaceutical products, wholesalers offer new services to address key logistical and commercial challenges for these therapies, although their roles and functions differ from conventional pharmaceutical products.

Understanding an Evolving Channel

This *2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors*—our 16th annual edition—remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. Widely regarded as the industry standard, this unique, encyclopedic resource is your ultimate guide to wholesale distribution’s role in the complex web of interactions within U.S. prescription drug channels.










Our definitive, nonpartisan resource thoroughly updates our annual exploration of the wholesale industry’s interactions with—and services for—other participants in our healthcare system. The report synthesizes a wealth of statistical data, research studies, financial information, and my own extensive experience. It will aid pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospital executives, pharmacy buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and anyone else who wants to understand and benefit from this ever-changing industry.

The 2025-26 edition contains the most current financial and industry data about the distribution of pharmaceuticals and the major companies that handle these products. As always, we have updated all market and industry data with the most current information available. The report also updates our annual analyses of the strategies, market positions, and executive compensation of the Big Three companies: Cencora, Cardinal Health, and McKesson. We review each wholesaler’s business segments and underlying business profitability, based upon our proprietary economic models. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance. Where appropriate, financial data have been restated based on updated disclosures.

The Big Three companies have each built significant positions in businesses beyond drug distribution. The chart on the next page highlights the vertical alignment of each company’s major businesses and those businesses’ diverse roles within the U.S. healthcare system. The numbers in the chart indicate the report chapter that explains and analyzes each business.

While conventional pharmaceutical wholesaling remains the most significant revenue source, each company has expanded both upstream and downstream from this base. The wholesalers market their own private-label generic drugs, operate pharmacy franchises, run businesses that negotiate with pharmacy benefit managers (PBMs) and other payers on behalf of their customers, provide group purchasing services for physician practices, provide patient and consulting services for their manufacturer suppliers, and many other businesses. Most recently, the companies’ strategic investments have focused on vertical integration into the management services organizations (MSO) that oversee physician practices in such clinical specialties as oncology, urology, and ophthalmology.

Exhibit 1: Vertical Alignment of Businesses Within Largest Wholesale Companies

X = Chapter Number		cencora ⑦	CardinalHealth™ ⑧	McKesson ⑨
Manufacturer ④				
Full-line wholesaling and specialty distribution ①				
Specialty pharmacy ③		—	—	
Retail pharmacy ② ⑥				
PSAO ②				
GPO ③				
Provider ③ ⑥				
Patient access services ①				
Wholesaler profitability (income statement): ④		Financial stability and cash flows (balance sheet): ⑤		

PSAO = pharmacy services administrative organizations; GPO = group purchasing organization
Source: Drug Channels Institute research. Exhibit does not illustrate every subsidiary business operated by each company.

What's New in the 2025-26 Report

The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors retains the overall structure of previous editions, and the chapters correspond to those of previous editions. Throughout the report, we have added new industry data, deepened our coverage of many topics, and added more trending information. In addition, selected material has been reorganized to reflect recent market developments.

The notable new material in this 2025-26 edition includes the following:

- [Section 3.2.2.](#) (page 104) adds new information about commercial payers' reimbursement for provider-administered biosimilar drugs.
- [Section 3.4.1.](#) (page 123) includes new proprietary data on hospitals' economics for prescription drug expenses.
- [Section 4.5.3.](#) (page 167) presents new data that quantifies the penetration of wholesalers' private-label generic drugs into government programs.
- A new [Section 6.1.5.](#) (page 211) evaluates the potential implications of most favored nation (MFN) and tariff policies on the wholesalers' businesses.
- [Section 6.2.4.](#) (page 225) has been expanded to cover new developments in cash-pay prescriptions and manufacturers' direct-to-patient channels.

- [Section 6.3.2.](#) (page 239) has been expanded to include more complete and current data on wholesalers’ acquisition of MSOs.
- [Section 6.5.](#) (page 264) has been revised to reflect the ongoing implementation of the Inflation Reduction Act (IRA).
 - In [Section 6.5.1.](#) (page 264), we update our review of key provisions of the law that relate to prescription drugs.
 - In [Section 6.5.2.](#) (page 269), we update our analyses of the IRA’s likely consequences for wholesalers and the overall pharmaceutical business.
- [Section 9.2.2.](#) (page 326) presents revenue and profit information for McKesson’s businesses based on restated 2025 financial information for the reporting structure that the company adopted during its 2026 fiscal year.
- Coverage of UnitedHealth Group’s Optum Rx wholesaler relationship has been moved to [Section 9.3.4.](#) (page 335), reflecting the business shift from Cardinal Health to McKesson.
- There are 187 exhibits in this 2025-26 edition, compared with the 178 exhibits in the 2024-25 edition. Most exhibits are new or fully updated from the previous year’s edition.

Structure of the 2025-26 Report

The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors analyzes the industry in a preface and three primary sections, comprising nine chapters in total.

[PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES](#) provides an integrated overview of the major themes that recur throughout our analysis. Each theme includes links to relevant chapters and sections within this report.

[SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS](#)

- [Chapter 1: Industry Overview](#) (page 10) defines the industry, describes business differences between full-line wholesaling and specialty distribution, summarizes wholesalers’ obligations under the DSCSA, explains wholesalers’ channel roles, analyzes the products that wholesalers sell, and reviews insurance coverage of these products. This chapter also identifies the major full-line wholesalers and specialty distributors, and it provides the latest data on their market share and revenues.
- [Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies](#) (page 38) analyzes the pharmacy market—the customer group that accounts for the majority of

wholesalers' revenues. It covers wholesalers' services for smaller pharmacies, wholesalers' participation in the pharmacy-PBM relationship via pharmacy services administrative organizations (PSAOs), and wholesalers' interactions with pharmacy buying groups.

The chapter also analyzes how wholesalers work with larger pharmacies. We include our proprietary analysis of the large generic sourcing consortia between wholesalers and the largest pharmacies. [Section 2.4.](#) (page 66) analyzes wholesalers' roles in the distribution of patient-administered drugs that specialty pharmacies dispense. We also consider wholesaler-owned specialty pharmacies.

- [Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals](#) (page 78) examines channels for provider-administered medications, explains the buy-and-bill system for drugs administered in outpatient settings, and describes the role and functions that wholesalers perform for hospitals, including hospitals that participate in the 340B Drug Pricing Program. This chapter also provides an in-depth consideration of group purchasing organizations (GPOs) for both hospitals and physician practices. It also includes material regarding pharmacy dispensing within buy-and-bill channels.

SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS

- [Chapter 4: Wholesaler Profitability](#) (page 143) delves into the industry's income statement economics to explain the underlying sources of drug distribution profits. We deconstruct buy-side and sell-side gross margin components, distinguish between sell-side profits from specialty and traditional drugs, and explain distribution service agreements (DSAs) with manufacturers. We analyze trends in overall gross margins and operating profits, as well as wholesalers' gross profits from brand-name, biosimilar, and generic drugs. This chapter explains how brand-name drug price inflation and deflation affects wholesalers' profits and examines wholesalers' operating expenses, operating profits, and employee compensation.
- [Chapter 5: Financial Stability and Cash Management](#) (page 179) provides our updated analyses of the key metrics that illustrate wholesalers' overall financial health. These include capital structures, debt (leverage), balance sheet assets, the cash conversion cycle, wholesalers' capital deployment and uses of cash, return on invested capital, and stock market valuation and performance. Chapter 5 also reviews and explains executive compensation at the Big Three wholesalers.
- [Chapter 6: Forces of Change for Drug Distribution](#) (page 199) updates our analysis of the key industry trends that will impact the market structure and economics of the pharmaceutical wholesaling and specialty distribution industries. It presents the outlook for the U.S. prescription market, wholesalers' projected revenues, brand-name and generic pricing, and MFN policy proposals. In addition, we update our analyses of

pharmacy and buy-and-bill markets, including trends related to manufacturers' direct-to-patient channel models, vertical integration activities by hospitals, acquisition of physician management service organizations by wholesalers, and cell and gene therapies. This chapter reviews the status of, and outlook for, pharmacy-dispensed and provider-administered biosimilars. Chapter 6 also contains material discussing importation from Canada, the national opioid settlement, and the IRA.

SECTION III: BIG THREE WHOLESALER COMPANY PROFILES

In this section, we analyze the latest financial data and strategies of the largest public companies. Each chapter provides parallel examinations of the Big Three public wholesalers. We scrutinize each company's business history, acquisitions and divestitures, business mix, profitability, largest customers, and company-specific business trends.

- [Chapter 7: Cencora](#) (page 284)
- [Chapter 8: Cardinal Health](#) (Page 306)
- [Chapter 9: McKesson Corporation](#) (page 320)

How to Use the 2025-26 Report

The chapters are self-contained and do not need to be read in order. We provide extensive internal clickable hyperlinks to help you navigate and customize the report to your specific needs. You can use keyboard shortcuts to return to your previous location in the document. We also encourage you to search the entire PDF document for every occurrence of a word or phrase. The shortcuts and search approach will vary based on your computer platform.

We offer more than [840 endnotes](#), most of which have hyperlinks to original source materials. We also provide a consolidated list of [Acronyms and Abbreviations](#) (page 342) for your reference.

As always, I welcome your feedback. Please contact me if you have any questions or comments about *The 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors*.

Adam J. Fein, Ph.D.
October 2025

P.S. [Click here for post-publication errata.](#)

CONTENTS

PREFACE: INDUSTRY TRENDS AND KEY REPORT THEMES.....	1
SECTION I: WHOLESALER AND CUSTOMER INDUSTRY ANALYSIS	9
Chapter 1: Industry Overview.....	10
1.1. Wholesale Industry Fundamentals	10
1.1.1. Defining Drug Wholesale Distribution.....	10
1.1.2. Full-Line Wholesalers	12
1.1.3. Specialty Distributors	14
1.1.4. Wholesalers and the Drug Supply Chain Security Act.....	16
1.2. The Products That Wholesalers Sell.....	20
1.2.1. Brand vs. Generic Drugs.....	20
1.2.2. Route of Administration and Benefit Coverage.....	21
1.2.3. Traditional vs. Specialty Drugs.....	22
1.3. Overview of Wholesalers’ Channel Roles.....	24
1.3.1. Physical Distribution	24
1.3.2. Financial Intermediation.....	26
1.3.3. Services for Pharmacies, Providers, and Manufacturers.....	27
1.3.4. Impact on Pharmacy and Provider Reimbursement.....	28
1.4. Industry Participants.....	29
1.4.1. Big Three Wholesalers: Revenue and Growth Trends	29
1.4.2. Specialty Product Distribution Market Share	33
1.4.3. Other Wholesale Market Participants.....	35
Chapter 2: Channel Role for Retail, Mail, and Specialty Pharmacies.....	38
2.1. The Pharmacy Market.....	38
2.1.1. Outpatient Dispensing Formats	39
2.1.2. Pharmacy Market Size and Structure.....	41
2.2. Independent Pharmacies	43
2.2.1. Industry Position and Wholesaler Relationships.....	44
2.2.2. Wholesaler Services for Independent Pharmacies.....	47
2.2.3. Franchise Programs and Marketing Groups.....	49
2.2.4. PSOs and the Wholesalers’ Role in Pharmacy-Payer Relationships	51
2.2.5. Pharmacy Group Purchasing Organizations and Wholesaler Relationships	57

2.2.6. Wholesaler Generic Source Programs for Smaller Pharmacies	59
2.3. Retail Chains and Mail Pharmacies	61
2.3.1. Wholesale Suppliers to Largest U.S. Pharmacies	61
2.3.2. Physical Distribution Relationships Between Wholesalers and Retail Chains	62
2.3.3. Generic Sourcing Relationships Between Wholesalers and Large Pharmacies	64
2.4. Specialty Pharmacies	66
2.4.1. Specialty Pharmacy Market Participants	67
2.4.2. Wholesalers’ Specialty Pharmacies	71
2.4.3. Wholesalers’ Role in Manufacturer-Defined Limited Specialty Networks	72
Chapter 3: Channel Role for Physician Offices/Clinics and Hospitals	78
3.1. The Provider-Administered Drug Market	78
3.1.1. Outpatient Drug Spending, Sites of Care, and Market Size	78
3.1.2. The Buy-and-Bill System	83
3.1.3. Group Purchasing Organizations (GPOs)	86
3.1.4. Contract Management and Chargebacks	87
3.1.5. White Bagging and Specialty Pharmacies’ Role in Buy-and-Bill Channels	89
3.2. Provider Reimbursement in the Buy-and-Bill System	98
3.2.1. Medicare Part B and Average Sales Price (ASP)	98
3.2.2. Commercial Health Plans	104
3.2.3. Patient Cost Sharing	110
3.3. Physician Offices	114
3.3.1. Pharmaceutical Purchasing and Distributors’ Services	114
3.3.2. Group Purchasing Organizations for Physician Practices	116
3.3.3. Specialty Drug Dispensing by Physician Practices	119
3.4. Hospitals	123
3.4.1. Pharmaceutical Purchasing and Wholesalers’ Services	123
3.4.2. Group Purchasing Organizations for Hospitals	129
3.4.3. Specialty Pharmacies at Hospitals and Health Systems	131
3.4.4. Wholesalers and the 340B Drug Pricing Program	136
SECTION II: BUSINESS ECONOMICS AND INDUSTRY TRENDS	142
Chapter 4: Wholesaler Profitability	143
4.1. Sources of Wholesaler Gross Profits and Gross Margin	144

4.2. Components of Buy-Side Gross Margin	144
4.2.1. Distribution Service Agreements.....	146
4.2.2. Payment Discounts	147
4.2.3. Specialty Distribution Service Agreements	148
4.2.4. Generic Sourcing Formularies.....	150
4.2.5. Provider-Administered Biosimilars.....	151
4.2.6. Wholesaler Compensation and Bona Fide Service Fees.....	153
4.3. Sell-Side Gross Margins and Cost-Minus Discounts.....	155
4.4. Gross Margins.....	157
4.4.1. Overall Gross Margins	157
4.4.2. Estimates of Buy-Side and Sell-Side Gross Margins.....	158
4.5. Gross Profits of Brand-Name, Biosimilar, and Generic Drugs.....	160
4.5.1. Life Cycle Profits for Traditional Generic Drugs	162
4.5.2. Life Cycle Profits for Provider-Administered Generic Drugs	165
4.5.3. Private Label Generic Drugs	167
4.6. The Profit Impact of Changes in Brand-Name Drug Prices.....	168
4.6.1. Wholesaler Fees and Brand-Name Drug Inflation or Deflation.....	169
4.6.2. Inventory Appreciation and Revaluation.....	174
4.7. Operating Expenses and Operating Profit.....	175
Chapter 5: Financial Stability and Cash Management.....	179
5.1. Debt, Coverage, and Liquidity Ratios.....	179
5.2. Balance Sheet Assets.....	182
5.3. Cash Conversion Cycle	182
5.3.1. Inventory Levels and Days Sales in Inventory.....	185
5.3.2. Accounts Receivable and Days Sales Outstanding	187
5.3.3. Accounts Payable and Days Payable Outstanding.....	190
5.4. Capital Deployment and Uses of Cash.....	191
5.5. Return on Invested Capital	192
5.6. Stock Market Performance.....	193
5.7. Executive Compensation.....	195
Chapter 6: Forces of Change for Drug Distribution	199
6.1. Industry Outlook.....	200

6.1.1. The Outlook for the U.S. Pharmaceutical Market and Wholesaler Revenues	200
6.1.2. The Outlook for Brand-Name Drug Prices and Wholesalers’ Strategic Responses	202
6.1.3. The Outlook for Generic Drug Prices	207
6.1.4. Update on National Opioid Settlement Payments	210
6.1.5. Implications of Most Favored Nation Pricing and Tariffs	211
6.2. Future Trends for Pharmacy Dispensing Channels	213
6.2.1. Impact of Pharmacy Market Evolution and Vertical Integration	213
6.2.2. Challenges from Specialty Prescription Growth and Wholesaler Strategic Responses	216
6.2.3. The Growth and Profitability of Specialty Generic Drugs for Wholesalers.....	222
6.2.4. Cash-Pay Prescriptions and Manufacturers’ Direct-to-Patient Channels.....	225
6.2.5. Importation From Canada.....	227
6.3. Future Trends for Buy-and-Bill Channels	231
6.3.1. Hospital Vertical Integration into Physician Practices	231
6.3.2. Acquisitions of Physician Management Service Organizations by Wholesalers.....	239
6.3.3. Wholesalers’ Roles in Channels for Cell and Gene Therapies	246
6.4. The Impact of Biosimilars on Wholesalers	250
6.4.1. 2025 Update on the Biosimilar Market.....	250
6.4.2. Biosimilars Under the Pharmacy Benefit.....	253
6.4.3. Biosimilars Under the Medical Benefit.....	258
6.5. The Inflation Reduction Act of 2022.....	264
6.5.1. Key Provisions of the IRA for Medicare Parts B and D	264
6.5.2. Wholesale Industry Implications of the Inflation Reduction Act	269
SECTION III: BIG THREE WHOLESALER COMPANY PROFILES.....	283
Chapter 7: Cencora	284
7.1. Business Overview	284
7.1.1. Company Information	284
7.1.2. Company History.....	284
7.1.3. Acquisitions and Divestitures	285
7.1.4. Business Segments.....	287
7.2. Profitability	290
7.2.1. Overall Pharmaceutical Distribution.....	290
7.2.2. Profitability by Business Sub-Segment.....	291

7.3. Customers.....	292
7.3.1. The 10 Largest Customers.....	292
7.3.2. Walgreens Boots Alliance	295
7.3.3. Evernorth Health Services.....	298
7.4. Growth Trends.....	301
7.4.1. U.S. Distribution Growth Trends	301
7.4.2. MWI Animal Health.....	301
7.4.3. Alliance Healthcare	303
Chapter 8: Cardinal Health.....	306
8.1. Business Overview	306
8.1.1. Company Information	306
8.1.2. Company History.....	306
8.1.3. Acquisitions and Divestitures	307
8.1.4. Business Segments.....	308
8.2. Profitability	310
8.2.1. Overall Pharmaceutical Distribution.....	310
8.2.2. Profitability by Business Sub-Segment.....	311
8.3. Customers.....	313
8.3.1. The 10 Largest Customers.....	313
8.3.2. CVS Health.....	315
8.4. Growth Trends.....	318
8.4.1. U.S. Distribution Growth Trends	318
8.4.2. Specialty Solutions.....	318
Chapter 9: McKesson Corporation.....	320
9.1. Business Overview	320
9.1.1. Company Information	320
9.1.2. Company History.....	320
9.1.3. Acquisitions and Divestitures	322
9.1.4. Business Segments.....	323
9.2. Profitability	325
9.2.1. Distribution Businesses	325
9.2.2. Profitability by Business Sub-Segment.....	326

9.3. Customers.....	328
9.3.1. Top 10 Largest Customers.....	328
9.3.2. CVS Health.....	330
9.3.3. Rite Aid	333
9.3.4. Optum Rx	335
9.4. Growth Trends.....	336
9.4.1. U.S. Drug Distribution Growth Trends	336
9.4.2. McKesson’s Specialty Businesses	337
9.4.3. McKesson Europe	338
9.4.4. McKesson Canada.....	339
Acronyms and Abbreviations.....	342
Endnotes	344

LIST OF EXHIBITS

Exhibit 1: Vertical Alignment of Businesses Within Largest Wholesale Companies.....	viii
Exhibit 2: Full-Line Wholesale Revenues, by Type of Customer, 2024.....	12
Exhibit 3: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2023	13
Exhibit 4: Full-Line Wholesalers, Inventory Levels and Product Sales, by Product Type, 2011 vs. 2023	13
Exhibit 5: Specialty Distributor Revenues, by Customer Type, 2023.....	14
Exhibit 6: Specialty Distributor Sales, by Therapeutic Area, 2023.....	15
Exhibit 7: Average Number of Manufacturers with Distribution Agreements for Specialty Distributors, 2015 to 2023.....	15
Exhibit 8: Distribution Center Operational Metrics, Full-Line Wholesalers vs. Specialty Distributors, 2023.....	16
Exhibit 9: Timeline of DSCSA Requirements for Pharmacies (Dispensers) and Wholesale Distributors, 2013 to 2026.....	17
Exhibit 10: Unbranded and Branded Generics, Share of U.S. Prescriptions, 2003 to 2024.....	20
Exhibit 11: Allowance for Doubtful Accounts at Big Three Wholesalers, by Company, 2024/2025	26
Exhibit 12: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, Calendar Year 2024	29
Exhibit 13: Market Share for U.S. Drug Distribution and Related Revenues, Big Three Wholesalers, 2014 vs. 2024.....	30
Exhibit 14: U.S. Drug Distribution and Related Revenues, Big Three Wholesalers, 2021 to 2025E	30
Exhibit 15: Revenues from GLP-1 Products, By Company, 2021 to 2025.....	31
Exhibit 16: Change in Quarterly U.S. Drug Distribution and Related Revenues, Big Three Wholesalers, 2021 to 2025.....	32
Exhibit 17: Specialty Product Distribution Revenues, by Division and Parent Company, 2024.....	33
Exhibit 18: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs.....	39
Exhibit 19: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2024	41
Exhibit 20: Independent Pharmacy Purchasing Source, by Product Type	44
Exhibit 21: Number of Independent Pharmacy Locations, 2001 to 2024.....	44
Exhibit 22: Independent Pharmacies as a Percentage of Full-Line Wholesaler Revenues, 2015 to 2024.....	45
Exhibit 23: Independent Pharmacies, Average Per-Prescription Gross Profits and Margins, 2019 to 2023.....	47
Exhibit 24: U.S. Pharmacy Franchise and Marketing Programs, 2024/2025.....	49
Exhibit 25: U.S. Pharmacy Franchise Locations, by Company, 2015 to 2025	50
Exhibit 26: Customer Satisfaction with Pharmacies, by Dispensing Format and Company, 2025	51
Exhibit 27: Largest Pharmacy Services Administrative Organizations, by Membership and Ownership, 2025 ..	54
Exhibit 28: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationships, by Number of Pharmacies, 2025	58

Exhibit 29: Wholesaler Generic Source Programs, Number of SKUs and Manufacturers, 2011 to 2024.....	60
Exhibit 30: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers, 2025.....	61
Exhibit 31: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2007 to 2023	63
Exhibit 32: Share of U.S. Generic Purchasing Volume, by Organization, 2025.....	64
Exhibit 33: Pharmacy Locations with Specialty Pharmacy Accreditation, by Corporate Ownership, 2024.....	68
Exhibit 34: Specialty Drug Prescription Revenues, by Dispensing Format, 2024	69
Exhibit 35: Prescription Revenues and Market Share from Specialty Pharmaceuticals, by Company, 2024.....	70
Exhibit 36: Specialty Pharmacy Networks, Participation Rate by Company, 2025.....	74
Exhibit 37: Alternative Channels to Specialty Pharmacies in Limited Dispensing Networks	75
Exhibit 38: Medical Benefit Spending on Outpatient Provider-Administered Drugs, by Drug Category and Payer, 2023.....	79
Exhibit 39: Spending for Outpatient Medical Benefit Drugs, by Site of Care and Payer, 2023	79
Exhibit 40: Medicare Advantage Spending for Outpatient Provider-Administered Drugs, by Site of Care and Drug, 2023.....	80
Exhibit 41: Commercial Medical Benefit Spending for Outpatient Provider-Administered Drugs, by Site of Care and Drug, 2023.....	81
Exhibit 42: Total Drug Purchases by Nonfederal Hospitals and Outpatient Clinics, 2018 to 2024	82
Exhibit 43: Components of Change in Total Provider-Administered Drug Purchases, Nonfederal Hospitals vs. Outpatient Clinics, 2024.....	82
Exhibit 44: Buy-and-Bill System for Distribution and Reimbursement of Provider-Administered Outpatient Drugs	83
Exhibit 45: Primary Roles of Third-Party Payer, Distributor, and Provider in Buy-and-Bill System.....	85
Exhibit 46: Share of Commercial Plan Sponsors Receiving Specialty Drug Rebates, Pharmacy vs. Medical Benefits, 2024	85
Exhibit 47: Chargebacks as a Percentage of Net Sales, Full-Line Wholesalers, 2009 to 2024.....	88
Exhibit 48: Reimbursement for Provider-Administered Specialty Drugs vs. Specialty Pharmacies, by Site of Care and Therapeutic Class, 2021	90
Exhibit 49: White Bagging Approach for Distribution and Reimbursement of Provider-Administered Outpatient Drugs.....	91
Exhibit 50: UnitedHealthcare, White Bagging Requirements for Hospital Outpatient Providers, by Specialty Pharmacy, 2025.....	92
Exhibit 51: Drug Sourcing for Infused Oncology Therapies, by Practice Type and Source, 2019 vs. 2024	93
Exhibit 52: Payer Reimbursement and Patient Out-of-Pocket Obligation for Oncology Drugs, White Bagging vs. Buy-and-Bill, 2020.....	94
Exhibit 53: Share of Hospitals Permitting Pharmacy Sourcing of Infused Drugs, by Source, 2020 vs. 2022.....	96
Exhibit 54: Distribution of Medicare Part B Add-on Payments, 2021.....	100
Exhibit 55: Reimbursement Method for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care	104

Exhibit 56: Reimbursement Method for Biosimilars of Provider-Administered Drugs Paid Under the Commercial Medical Benefit, 2021.....	105
Exhibit 57: Distribution of Hospitals’ Cost-to-Charge Ratio for Pharmaceuticals, 2023	105
Exhibit 58: Reimbursement Rate and Administration Cost for Provider-Administered Drugs Paid Under the Commercial Medical Benefit, by Site of Care, 2024	106
Exhibit 59: Markups for Provider Administered Specialty Drugs for Privately Insured Individuals, by Site of Care and 340B Status, 2020/2021	107
Exhibit 60: Commercial Medical Benefit Cost per Claim for Reference Biologics and Their Biosimilars, by Site of Care, 2019 to 2023.....	107
Exhibit 61: Hospital Reimbursement by Commercial Payers, Avastin and Its Biosimilars, by Payer and Product, 2025.....	109
Exhibit 62: Commercial Health Plans’ Site-of-Care Programs for Provider-Administered Specialty Drugs, by Plan Type, 2024.....	109
Exhibit 63: Cigna Healthcare, Number of Specialty Drugs Subject to Site-of-Care Medical Policy, 2018 to 2025	110
Exhibit 64: Patient Cost Sharing for Provider-Administered Drugs	111
Exhibit 65: Medicare Part B Coinsurance Adjustments, 2023:Q2 to 2025:Q1	112
Exhibit 66: Annual Rebate per Medicare Advantage Beneficiary, by Extra Benefit Type, 2020 to 2025	114
Exhibit 67: Revenue Mix at Oncology Practices, by Category	115
Exhibit 68: Specialty Physician Practice GPOs and Ownership, 2025	117
Exhibit 69: Share of Oncologists in Practices with Medically Integrated Dispensing, by Practice Setting, 2010 to 2024.....	121
Exhibit 70: Initial and Final Prescription Claim Status for Brand-Name Oral Oncology Therapies, by Site of Dispensing, 2023	122
Exhibit 71: U.S. Hospitals, by Type and Ownership, 2023	124
Exhibit 72: Share of Community Hospitals, by Health System Affiliation, 1993 to 2023	124
Exhibit 73: Hospital Mergers & Acquisitions, Total Announced Transacted Revenue, 2011 to 2025	125
Exhibit 74: Ten Largest Integrated Delivery Networks, by Net Patient Revenues, 2023.....	125
Exhibit 75: Hospital Operating Expenses, by Type of Expense, 2024	126
Exhibit 76: Prescription Drug Costs as a Percentage of Hospital Expenses, 2014 to 2024.....	126
Exhibit 77: Change in Hospital Drug Expense per Adjusted Discharge, 2020 to 2025.....	127
Exhibit 78: Total Cost of Drugs and Cost-to-Charge Ratio, Top 10 Hospitals, 2023	127
Exhibit 79: Number and Share of Pharmacists Employed by Hospitals, 2010 to 2024.....	128
Exhibit 80: Number of Inpatient Pharmacists and Pharmacy Technicians per 100 Occupied Hospital Beds, 2019 to 2024.....	129
Exhibit 81: Largest Group Purchasing Organizations, by Membership and Total Purchasing Volume, 2025 ..	130
Exhibit 82: Hospital and Clinic Share of Oral Oncology Market, 2017 to 2024	134
Exhibit 83: Hospitals’ Perceived Barriers to Accessing Specialty Pharmacy Networks, 2020 vs. 2022.....	135

Exhibit 84: 340B Drug Pricing Program, Purchases by Covered Entities, 2010 to 2024	137
Exhibit 85: 340B Contract Pharmacy Relationships with Hospitals, by Company, 2020 vs. 2025	138
Exhibit 86: Key Elements on a Wholesaler’s Income Statement.....	143
Exhibit 87: Sources of a Wholesaler’s Gross Margin from Brand-Name Drugs	144
Exhibit 88: U.S. Core Drug Distribution Gross Margin, Big Three Wholesalers, 2021 to 2025	157
Exhibit 89: U.S. Drug Distribution Gross Profits, Big Three Wholesalers, Total and Annual Change, 2021 to 2025.....	158
Exhibit 90: Estimated Buy-Side and Sell-Side Contributions to Wholesalers’ Gross Margin, 2025.....	158
Exhibit 91: Estimated Drug Distribution Gross Margin, by Drug and Customer Type, 2025.....	160
Exhibit 92: Revenues and Gross Profits, Big Three Wholesalers, by Type of Drug, 2025.....	161
Exhibit 93: Median Wholesaler Sell-Side Discount for Generic Drugs Sold to Retail Pharmacies, by Number of Manufacturers, 2025.....	163
Exhibit 94: Path of Wholesaler Gross Profits, Brand vs. Multisource Generic Drug.....	165
Exhibit 95: Example of Channel Profits from a Provider-Administered Generic Drug.....	166
Exhibit 96: Medicare Part D and Medicaid Prescription Reimbursement for Wholesalers’ Private Label Generic Drugs, By Company, 2019 to 2023.....	168
Exhibit 97: Brand-Name Drugs, Change in Average List and Net Prices, 2014 to 2025	169
Exhibit 98: Illustrative Value of a Wholesaler’s Buy-Side Fees with Alternative Brand-Name Pharmaceutical Price Inflation Scenarios	171
Exhibit 99: Price Indices for Warehousing & Storage and Truck Transportation, 2020 to 2025	172
Exhibit 100: Illustrative Value of a Wholesaler’s Buy-Side Fees with Brand-Name Pharmaceutical Price Deflation.....	173
Exhibit 101: Illustrative Effect of Inventory Revaluation on a Wholesaler’s Gross Profit.....	175
Exhibit 102: Full-Line Wholesalers, Operating Expenses, by Category, 2021 to 2023	176
Exhibit 103: Median Annual Total Employee Compensation, by Company, 2024.....	176
Exhibit 104: Drug Distribution Operating Profit Margin as a Percentage of Revenues, Big Three Wholesalers, 2021 to 2025.....	177
Exhibit 105: Total Corporate Operating Profits as a Percentage of Total Corporate Gross Profits, Big Three Wholesalers, 2025	178
Exhibit 106: Total Debt Including Interest Payments, Big Three Wholesalers, 2025.....	179
Exhibit 107: Debt-to-EBITDA Ratio, Big Three Wholesalers, FY2023 to FY2025	181
Exhibit 108: Liquidity Ratios, Big Three Wholesalers, FY2025.....	181
Exhibit 109: Composition of Current Assets, Big Three Wholesalers, 2025.....	182
Exhibit 110: Illustrative Wholesaler Cash Conversion Cycle for Brand-Name Drugs Sold to a Pharmacy.....	183
Exhibit 111: Cash Conversion Cycle, Big Three Wholesalers, 2025	184
Exhibit 112: Cash Conversion Cycle, Big Three Wholesalers, 2015 to 2025.....	185
Exhibit 113: Days Sales in Inventory, Big Three Wholesalers, 2021 to 2025.....	186
Exhibit 114: Days Sales Outstanding, Big Three Wholesalers, 2021 to 2025	187

Exhibit 115: Percentage of Wholesalers' Trade Accounts Receivable and DSO for Largest Customers, 2025	188
Exhibit 116: Days Payable Outstanding, Big Three Wholesalers, 2021 to 2025	190
Exhibit 117: Capital Deployment, Big Three Wholesalers, FY2021 to FY2025.....	191
Exhibit 118: Dividends and Share Repurchases as a Percentage of Operating Cash Flow, Big Three Wholesalers, FY2023 to FY2025.....	192
Exhibit 119: Return on Invested Capital, Big Three Wholesalers, 2019 to 2025.....	193
Exhibit 120: Forward Price-to-Earnings Ratio, Big Three Wholesalers vs. S&P 500, 2014 to 2025.....	194
Exhibit 121: One- and Five-Year Stock Price Performance, Big Three Wholesalers vs. Manufacturers and Overall Market	194
Exhibit 122: Components of CEO Compensation, Big Three Wholesalers, 2024/25	195
Exhibit 123: Financial Metrics Used for Annual Cash Incentive Compensation, Big Three Wholesalers, 2024/25	196
Exhibit 124: Financial Metrics Used for Long-Term Incentive Compensation, Big Three Wholesalers, 2024/25	197
Exhibit 125: U.S. Gross Manufacturer Revenues, Annual Total and Growth, 2019 to 2029.....	200
Exhibit 126: Total Value Lost to Generic and Biosimilar Launches, by Product Type, 2021 to 2029.....	201
Exhibit 127: U.S. Drug Distribution and Related Revenues, Big Three Wholesalers, 2019 to 2029	201
Exhibit 128: Summary of List Price Reductions for Selected Brand-Name Drugs, 2024/2025.....	205
Exhibit 129: Average Year-over-Year Change in Pricing of Mature Generic Drugs, Oral vs. Injectable, 2015 to 2025.....	208
Exhibit 130: Generic Drug Approvals, FDA, 2014 to 2025.....	209
Exhibit 131: National Opioid Settlement Payments, by Company, 2025	211
Exhibit 132: Vertical Business Relationships Within the U.S. Drug Channel, 2025	214
Exhibit 133: Pharmacy Industry Prescription Revenues, Traditional vs. Specialty Drugs, 2019 to 2029	217
Exhibit 134: Top Specialty Therapy Categories, Generic Drugs as a Share of Prescriptions and Net Spending, 2024.....	222
Exhibit 135: Nonbiological Specialty Drugs, Pharmacy Acquisition Cost per Unit for Brand-Name vs. Generic Version, 2024.....	223
Exhibit 136: Dispensing Spreads for Specialty Generic Drugs at PBM-Affiliated Pharmacies, 2017 to 2021....	224
Exhibit 137: Physician Employment, by Practice Ownership, 2012 vs. 2024	232
Exhibit 138: Number of Physicians per Practice, by Practice Ownership, 2024	232
Exhibit 139: U.S. Physician Employment, by Specialty and Employer Type, 2022	233
Exhibit 140: Number of U.S. Physicians Employed by Hospitals/Health Systems, 2019 to 2024	233
Exhibit 141: Acquisitions of Community Oncology Practices, by Type of Acquirer, 2010 to 2024	234
Exhibit 142: Share of Medicare Part B Fee-For-Service Spending on Provider-Administered Outpatient Drugs, by Location of Service, 2008 to 2023	235
Exhibit 143: Share of Specialty Distributor Revenues, by Customer Type, 2011 to 2023	236
Exhibit 144: Number of Private Equity Acquisitions of Physician Practices, 2013 to 2025.....	240

Exhibit 145: Management Service Organizations Acquired by Large Wholesalers, 2023 to 2025.....	241
Exhibit 146: Revenue Sources at Community Physician Practices, By Specialty, 2025	244
Exhibit 147: Number of U.S. Biosimilar Approvals, 2015 to 2025	251
Exhibit 148: Physician Perceptions of Biosimilars, by Specialty, 2023	253
Exhibit 149: Formulary Coverage and Pricing for Humira and Its Biosimilars, by PBM, 2025.....	254
Exhibit 150: Formulary Coverage and Pricing for Stelara and Its Biosimilars, by PBM, 2025	257
Exhibit 151: FDA-Approved Biosimilars, Provider-Administered Drugs, 2025	258
Exhibit 152: Market Share of Provider-Administered Biosimilars, 2020 vs. 2025.....	259
Exhibit 153: Provider-Administered Oncology Drugs, Prices of Biosimilars vs. Reference Product, 2025	259
Exhibit 154: Formulary Coverage Status of Provider-Administered Drugs at U.S. Commercial Payers, Reference Products vs. Biosimilars, 2017 to 2022.....	262
Exhibit 155: Payer Formulary Coverage of Provider-Administered Oncology Biosimilars, 2022 to 2024.....	263
Exhibit 156: Standard Medicare Prescription Drug Benefit, 2024 vs. 2025	266
Exhibit 157: Prices for Products Selected for 2026 Medicare Drug Price Negotiation Program, by Total and Out-of-Pocket Spending.....	268
Exhibit 158: Quarterly Change in Specialty Drug Utilization, by Beneficiary Income, 2024	271
Exhibit 159: Number of Stand-Alone Medicare Part D Prescription Drug Plans, 2007 to 2026	272
Exhibit 160: Illustrative Effect of Inflation Reduction Act on Medicare Part B Margins, 340B Hospitals vs. Community Practices.....	280
Exhibit 161: Cencora, Pharmaceutical Distribution Segment, Profitability Metrics, 2021 to 2025.....	291
Exhibit 162: Cencora, Estimated Revenues and Operating Profit, by Segment, FY2025E.....	292
Exhibit 163: Cencora, Top 10 U.S. Drug Distribution Customers, FY2025	293
Exhibit 164: Cencora, Revenues from Walgreens Boots Alliance, 2015 to 2025	295
Exhibit 165: Cencora, Days Sales Outstanding from Walgreens and Express Scripts vs. All Other Customers, 2021 to 2025.....	298
Exhibit 166: Cencora, Revenues from Evernorth Health Services, 2014 to 2025	299
Exhibit 167: Evernorth Health Services, Pharmacy Dispensing Revenues vs. Pharmaceutical Purchases Through Cencora, 2014 to 2025	300
Exhibit 168: Cencora, U.S. Pharmaceutical Distribution, Revenues and Growth, 2020:Q1 to 2025:Q2	301
Exhibit 169: MWI Animal Health, Revenues and Growth, 2021 to 2025.....	302
Exhibit 170: Animal Health Products Distribution Market Share, by Company and Segment, 2014 vs. 2025	303
Exhibit 171: Number of Pharmacies per Capita, Major European Countries, 2023	304
Exhibit 172: Alliance Healthcare, Revenues and Growth, 2021 to 2025	305
Exhibit 173: Cardinal Health, Profitability Metrics, 2021 to 2025.....	311
Exhibit 174: Cardinal Health, Estimated Revenues and Operating Profit, by Segment, FY2025	312
Exhibit 175: Cardinal Health, Top 10 U.S. Drug Distribution Customers, FY2025	313
Exhibit 176: Cardinal Health, Revenues from CVS Health, 2010 to 2025	316

Exhibit 177: Cardinal Health, Days Sales Outstanding from CVS Health and Optum Rx vs. All Other Customers, 2021 to 2025.....	317
Exhibit 178: Cardinal Health, U.S. Pharmaceutical Distribution, Revenues and Growth, 2021:Q1 to 2025:Q2	318
Exhibit 179: McKesson, Distribution Businesses, Gross and Segment Operating Profitability Metrics, 2021 to 2025.....	326
Exhibit 180: McKesson, Estimated Revenues and Operating Profit, by Segment, FY2025.....	327
Exhibit 181: McKesson, Top 10 U.S. Drug Distribution Customers, FY2025	328
Exhibit 182: McKesson, Revenues from CVS Health, 2011 to 2025.....	330
Exhibit 183: McKesson, Days Sales Outstanding, CVS Health vs. All Other Customers, 2021 to 2025	333
Exhibit 184: McKesson, Revenues from Rite Aid, 2016 to 2025	334
Exhibit 185: Cardinal Health, Revenues from Optum Rx, 2016 to 2024.....	335
Exhibit 186: McKesson, U.S. Pharmaceutical Distribution, Revenues and Growth, 2021:Q1 to 2025:Q2	337
Exhibit 187: McKesson Canada, Revenues and Growth, 2021 to 2025.....	340